News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call Transcript August 11, 2025 Arcturus Therapeutics Holdings Inc. beats earnings expectations.
Citi raised the firm’s price target on Arcturus Therapeutics (ARCT) to $49 from $47 and keeps a Buy rating on the shares. The firm believes the ARC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback